{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/FULC/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-10T21:10:37.880Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":6775,"canonical_name":"Fulcrum Therapeutics, Inc.","cik":"0001680581","uei":null,"lei":null,"duns":null,"ticker":"FULC"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":35},"count":35,"timeline":[{"ts":"2026-07-28","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Fulcrum Therapeutics, Inc. — 2026-07-28","url_slug":"/sec/cik-0001680581/schedule-13g-a/0002012383-26-002576","accession_number":"0002012383-26-002576","importance":30},{"ts":"2026-07-17","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Fulcrum Therapeutics, Inc. — 2026-07-17","url_slug":"/sec/cik-0001680581/schedule-13g/0002052113-26-000745","accession_number":"0002052113-26-000745","importance":55},{"ts":"2026-07-17","kind":"sec.insider.p","reporter":"TANG KEVIN","title":"","shares":50945,"price_per_share":3.52,"usd_value":179326,"security_title":"Common Stock","importance":50.1793264},{"ts":"2026-07-17","kind":"sec.insider.p","reporter":"TANG CAPITAL MANAGEMENT LLC","title":"","shares":50945,"price_per_share":3.52,"usd_value":179326,"security_title":"Common Stock","importance":50.1793264},{"ts":"2026-07-16","kind":"sec.insider.p","reporter":"TANG KEVIN","title":"","shares":116671,"price_per_share":3.56,"usd_value":415349,"security_title":"Common Stock","importance":50.41534876},{"ts":"2026-07-16","kind":"sec.insider.p","reporter":"TANG CAPITAL MANAGEMENT LLC","title":"","shares":116671,"price_per_share":3.56,"usd_value":415349,"security_title":"Common Stock","importance":50.41534876},{"ts":"2026-07-15","kind":"sec.insider.p","reporter":"TANG KEVIN","title":"","shares":107377,"price_per_share":3.56,"usd_value":382262,"security_title":"Common Stock","importance":50.38226212},{"ts":"2026-07-15","kind":"sec.insider.p","reporter":"TANG CAPITAL MANAGEMENT LLC","title":"","shares":107377,"price_per_share":3.56,"usd_value":382262,"security_title":"Common Stock","importance":50.38226212},{"ts":"2026-07-15","kind":"sec.insider.107377","reporter":"TANG KEVIN","title":null,"shares":107377,"price_per_share":3.56,"usd_value":382262,"security_title":"Common Stock","importance":15.38226212},{"ts":"2026-07-14","kind":"sec.insider.p","reporter":"TANG KEVIN","title":"","shares":75952,"price_per_share":3.58,"usd_value":271908,"security_title":"Common Stock","importance":50.27190816},{"ts":"2026-07-14","kind":"sec.insider.p","reporter":"TANG CAPITAL MANAGEMENT LLC","title":"","shares":75952,"price_per_share":3.58,"usd_value":271908,"security_title":"Common Stock","importance":50.27190816},{"ts":"2026-07-14","kind":"sec.insider.p","reporter":"TANG KEVIN","title":"","shares":53651,"price_per_share":3.56,"usd_value":190998,"security_title":"Common Stock","importance":50.19099756},{"ts":"2026-07-14","kind":"sec.insider.p","reporter":"TANG CAPITAL MANAGEMENT LLC","title":"","shares":53651,"price_per_share":3.56,"usd_value":190998,"security_title":"Common Stock","importance":50.19099756},{"ts":"2026-07-14","kind":"sec.insider.75952","reporter":"TANG KEVIN","title":null,"shares":75952,"price_per_share":3.58,"usd_value":271908,"security_title":"Common Stock","importance":15.27190816},{"ts":"2026-07-14","kind":"sec.insider.53651","reporter":"TANG KEVIN","title":null,"shares":53651,"price_per_share":3.56,"usd_value":190998,"security_title":"Common Stock","importance":15.19099756},{"ts":"2026-07-13","kind":"sec.insider.p","reporter":"TANG KEVIN","title":"","shares":12966,"price_per_share":3.54,"usd_value":45900,"security_title":"Common Stock","importance":50.04589964},{"ts":"2026-07-13","kind":"sec.insider.p","reporter":"TANG CAPITAL MANAGEMENT LLC","title":"","shares":12966,"price_per_share":3.54,"usd_value":45900,"security_title":"Common Stock","importance":50.04589964},{"ts":"2026-07-13","kind":"sec.insider.12966","reporter":"TANG KEVIN","title":null,"shares":12966,"price_per_share":3.54,"usd_value":45900,"security_title":"Common Stock","importance":15.04589964},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — King Rachel K. — 2026-07-02","url_slug":"/sec/cik-0001589712/4/0001193125-26-294691","accession_number":"0001193125-26-294691","importance":30},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — Dorton Katina — 2026-07-02","url_slug":"/sec/cik-0001617541/4/0001193125-26-294699","accession_number":"0001193125-26-294699","importance":30},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — Fulcrum Therapeutics, Inc. — 2026-07-02","url_slug":"/sec/cik-0001680581/4/0001193125-26-294703","accession_number":"0001193125-26-294703","importance":30},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — Fulcrum Therapeutics, Inc. — 2026-07-02","url_slug":"/sec/cik-0001680581/4/0001193125-26-294680","accession_number":"0001193125-26-294680","importance":30},{"ts":"2026-06-30","kind":"sec.filing","form_type":"4","title":"4 — Fulcrum Therapeutics, Inc. — 2026-06-30","url_slug":"/sec/cik-0001680581/4/0001193125-26-290622","accession_number":"0001193125-26-290622","importance":30},{"ts":"2026-06-26","kind":"sec.form144","reporter":"ALAN EZEKOWITZ","title":"Director","shares":18000,"usd_value":64980,"security_title":"Common","approx_sale_date":"2026-06-26","accession_number":"0001950047-26-006549","importance":40.012996},{"ts":"2026-06-26","kind":"sec.insider.s","reporter":"Ezekowitz Alan","title":null,"shares":18000,"price_per_share":3.6452,"usd_value":65614,"security_title":"Common Stock","importance":35.0656136},{"ts":"2026-06-26","kind":"sec.filing","form_type":"144","title":"144 — Fulcrum Therapeutics, Inc. — 2026-06-26","url_slug":"/sec/cik-0001680581/144/0001950047-26-006549","accession_number":"0001950047-26-006549","importance":30},{"ts":"2026-06-25","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — EcoR1 Capital, LLC — 2026-06-25","url_slug":"/sec/cik-0001587114/schedule-13g/0000935836-26-000330","accession_number":"0000935836-26-000330","importance":55},{"ts":"2026-06-25","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — EcoR1 Capital, LLC — 2026-06-25","url_slug":"/sec/cik-0001587114/schedule-13g/0000935836-26-000331","accession_number":"0000935836-26-000331","importance":55},{"ts":"2026-06-25","kind":"sec.filing","form_type":"8-K","title":"8-K — Fulcrum Therapeutics, Inc. — 2026-06-25","url_slug":"/sec/cik-0001680581/8-k/0001193125-26-282873","accession_number":"0001193125-26-282873","importance":35},{"ts":"2026-06-11","kind":"sec.filing","form_type":"8-K","title":"8-K — Fulcrum Therapeutics, Inc. — 2026-06-11","url_slug":"/sec/cik-0001680581/8-k/0001193125-26-267659","accession_number":"0001193125-26-267659","importance":35},{"ts":"2026-06-04","kind":"sec.filing","form_type":"8-K","title":"8-K — Fulcrum Therapeutics, Inc. — 2026-06-04","url_slug":"/sec/cik-0001680581/8-k/0001193125-26-257376","accession_number":"0001193125-26-257376","importance":35},{"ts":"2026-06-01","kind":"sec.filing","form_type":"8-K","title":"8-K — Fulcrum Therapeutics, Inc. — 2026-06-01","url_slug":"/sec/cik-0001680581/8-k/0001193125-26-251394","accession_number":"0001193125-26-251394","importance":35},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Fulcrum Therapeutics, Inc. — 2026-05-15","url_slug":"/sec/cik-0001680581/schedule-13g-a/0001193125-26-226891","accession_number":"0001193125-26-226891","importance":30},{"ts":"2026-04-27","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Fulcrum Therapeutics, Inc. — 2026-04-27","url_slug":"/sec/cik-0001680581/10-q/0001193125-26-178814","accession_number":"0001193125-26-178814","importance":45},{"ts":"2026-04-27","kind":"sec.filing","form_type":"8-K","title":"8-K — Fulcrum Therapeutics, Inc. — 2026-04-27","url_slug":"/sec/cik-0001680581/8-k/0001193125-26-178806","accession_number":"0001193125-26-178806","importance":35}]}